News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Sunovion Announces Positive Results from Study of Apomorphine Sublingual Film in Patients with PD


(January 30, 2018) – Sunovion Pharmaceuticals Inc. announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes). Study CTH-300 met its primary and key secondary endpoints, and the medicine was also generally well-tolerated by study participants. Read more…